SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-12-061296
Filing Date
2012-11-13
Accepted
2012-11-13 11:20:12
Documents
11
Period of Report
2012-09-30
Confirming Copy
 

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q v325645_10q.htm 10-Q 408545
2 EXHIBIT 31.1 v325645_ex31-1.htm EX-31.1 7590
3 EXHIBIT 31.2 v325645_ex31-2.htm EX-31.2 7535
4 EXHIBIT 32.1 v325645_ex32-1.htm EX-32.1 3534
5 EXHIBIT 32.2 v325645_ex32-2.htm EX-32.2 3401
  Complete submission text file 0001144204-12-061296.txt   3540882

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT navb-20120930.xml EX-101.INS 336219
8 XBRL TAXONOMY EXTENSION SCHEMA navb-20120930.xsd EX-101.SCH 42501
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20120930_cal.xml EX-101.CAL 53572
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20120930_def.xml EX-101.DEF 89432
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20120930_lab.xml EX-101.LAB 576574
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20120930_pre.xml EX-101.PRE 250027
Mailing Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017
Business Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences